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Abstract 
Background: Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), a newly discovered long intergenic 
noncoding RNA (lincRNA), has been reported to be aberrantly expressed in various cancers, and may serve as a novel 
potential biomarker for cancer prognosis. This meta-analysis was conducted to investigate the effects of MALAT1 on 
cancer prognosis and lymph node metastasis.
Methods: A quantitative meta-analysis was performed using a systematic search of PubMed, Medline and Web of 
Science databases to identify eligible papers on prognostic value of MALAT1 in cancers. The pooled hazard ratios 
(HRs) or odds ratios (OR) with a 95 % confidence interval (95 % Cl) were calculated to evaluate its prognostic value.
Results: A total of 2094 patients from 17 studies between 2003 and 2016 were included. The results revealed 
that elevated MALAT1 expression was significantly associated with poor overall survival (OS) in 11 types of cancers 
(HR = 1.91, 95 % CI 1.49–2.34). Furthermore, subgroup analysis indicated that region of study (Germany, Japan or 
China), cancer type (digestive system cancers, urinary system cancers or respiratory system cancers) and sample size 
(more or less than 100) did not alter the significant predictive value of MALAT1 in OS from various types of cancer. In 
addition, upregulation of MALAT1 expression was significantly associated with poor disease-free survival (HR = 2.29, 
95 % CI 1.24–3.35), and recurrence-free survival (HR = 2.09, 95 % CI 0.81–3.37). The results showed that the incidence 
of lymph node metastasis was higher in high MALAT1 expression group than that in low MALAT1 expression group 
(OR = 1.67, 95 % CI 1.30–2.15).
Conclusions: This meta-analysis revealed that elevated MALAT1 expression may serve as a novel predictive bio-
marker for poor survival and lymph node metastasis in different types of cancer.
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Background
Cancer has now become a major cause of morbid-
ity and mortality in most regions worldwide, and the 
5-year survival rate remains low in a wide types of can-
cer (Bray et al. 2013). With the development of genome-
wide sequencing technology, numerous investigators are 
searching for biomarkers that may help with the clinical 
diagnosis or prognostic prediction of various cancers. 
Recently, long noncoding RNAs (lncRNAs) have caught 
increasing attention, and might act as potential valuable 
biomarkers for cancer diagnosis or potential targets for 
cancer therapy (Esteller 2011; Gibb et al. 2011).
LncRNAs are generally defined as transcribed RNA 
molecules with a length greater than 200 nt, and most 
lack protein coding capability. However, accumulat-
ing evidences have suggested that lncRNAs participated 
in a wide range of biological pathways. LncRNAs could 
gene expression through diverse molecular mecha-
nisms, including transcriptional and post–transcriptional 
processing, chromatin modification and epigenetics, 
genomic imprinting, protein activity modulation and 
protein localization. Recent studies found that dysregula-
tion of lncRNAs is always associated with cancer devel-
opment and progression (Zhang et al. 2014; Wang et al. 
2014). Importantly, lncRNAs could play important regu-
lators in various cancer-related processes such as modu-
lation of apoptosis and proliferation, drug resistance and 
the process of epithelial-mesenchymal transition (EMT) 
(Yang et al. 2014). However, the role of most lncRNAs in 
cancer progression and prognosis still remains unclear.
Metastasis associated in lung adenocarcinoma tran-
script 1 (MALAT1) is a highly conserved nuclear-abun-
dant lncRNA with more than 8000 nucleotides derived 
from chromosome 11q13. It was the first lncRNA that 
identified as a prognostic biomarker for early stage non-
small cell lung cancer (Ji et  al. 2003; Guru et  al. 1997; 
van Asseldonk et  al. 2000). Up-regulation of MALAT1 
expression was reported in a variety of cancers, including 
non-small cell lung cancer (Ji et  al. 2003; Schmidt et al. 
2011), hepatocellular carcinoma (Lai et  al. 2012), gas-
tric cancer (Okugawa et al. 2014), pancreatic cancer (Liu 
et  al. 2014; Pang et  al. 2015), colorectal cancer (Zheng 
et al. 2014), clear cell renal cell carcinoma (Zhang et al. 
2015), esophageal cancer (Hu et  al. 2015; Huang et  al. 
2016a), gallbladder cancer (Wang et  al. 2016), bladder 
cancer (Fan et al. 2014), osteosarcoma (Dong et al. 2015) 
and breast cancer (Huang et al. 2016b; Miao et al. 2016). 
MALAT1 is thought to regulate tumor cell viability, inva-
siveness and migration (Yoshimoto et  al. 2016). Recent 
study found that knock-down of MALAT1 expression 
could inhibit pancreatic cancer cell proliferation, migra-
tion, invasion and the process of epithelial-mesenchymal 
transition, and induce cell apoptosis and G2/M cell cycle 
arrest in  vitro (Jiao et  al. 2014). Moreover, Dong et  al. 
found that that MALAT1 might promote the prolifera-
tion and metastasis of osteosarcoma cells by activating 
the PI3 K/Akt signaling pathway (Dong et al. 2015). Lai 
et  al. demonstrated that downregulation of MALAT1 
expression in HepG2 cells suppressed cell viability, motil-
ity, and invasiveness and elevated the sensitivity to apop-
tosis (Lai et al. 2012).
A number of studies have revealed that overexpression 
of MALAT1 was significantly associated with high-risk 
grade, metastasis and patients’ survival in many types of 
cancers (Xia et al. 2016; Wang et al. 2016; Li et al. 2016). 
Although MALAT1 expression is considered to relat-
ing to clinical prognosis of multiple cancers, the specific 
impact of MALAT1 expression on the outcome of can-
cer patients still needs to be further investigated. There-
fore, we conducted a systematic review and quantitative 
meta-analysis to further investigate the prognostic role of 
MALAT1 overexpression in human cancers.
Methods
Literature collection
The selected literatures were determined via an electronic 
search of PubMed, EMBASE, Web of Science, Ovid and 
Cochrane library databases using these following terms: 
“MALAT1”, “NEAT2”, “long intergenic noncoding RNA”, 
“lincRNA”, “lncRNA”, “noncoding RNA”, “cancer”, ‘‘car-
cinoma”, “neoplasm”, “outcome”, “prognosis”, “prognos-
tic”, “mortality”, “survival”, “metastasis”, “recurrence” and 
“lymph node metastasis”. The literature search, which was 
performed by two independent researchers, was limited 
to the English language. The last search was updated in 
August 28, 2016. The reference lists of the retrieved arti-
cles were searched manually.
Inclusion and exclusion criteria
The studies were considered eligible if they met the fol-
lowing criteria: any type of human cancer was studied; 
studies investigating the prognostic role of MALAT1 
in various cancers; the levels of MALAT1 expression in 
cancerous tissues were detected; patients were grouped 
according to the levels of MALAT1 expression; a link 
between MALAT1 expression and clinicopathologic 
parameters was included; studies providing sufficient 
data to estimate the HRs with corresponding 95  % CI 
for overall survival (OS), disease specific survival (DSS), 
disease-free survival (DFS) or disease-free survival 
(RFS); and studies published in English. Exclusion cri-
teria were as follows: letters, editorials, expert opinions, 
case reports and reviews; studies only investigated the 
molecular structure and functions of MALAT1; studies 
without usable data for further analysis; and duplicate 
publications.
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Data extraction
Two investigators (PS, YZ) independently evaluated and 
extracted data from each identified studies based on cri-
teria of inclusion and exclusion. Corresponding authors 
were contacted to clarify missing or ambiguous data. 
The following information was carefully extracted: first 
author, publication date, country, ethnicity, tumor type, 
sample size, detection method, follow-up period, cut-off 
value, the number of high and low MALAT1 expression, 
the number of patients with lymph node metastasis, sur-
vival analysis methodology, HRs with corresponding 95 % 
CIs for OS, DSS, RFS or DFS. HRs with corresponding 
95 % CIs were preferentially extracted from univariate or 
multivariate analyses. If these were not available, the HR 
estimates were calculated from Kaplan–Meier survival 
curves using Engauge Digitizer V4.1 (http://sourceforge.
net).
Statistical analyses
All data analyses were performed with STATA statistical 
software version 14.0 (Stata Corporation, College Sta-
tion, TX, USA). Pooled HRs with 95 % CIs were used to 
estimate the strength of the link between MALAT1 and 
clinical prognosis. X2-based Cochran Q test and Higgins 
I2 statistic were utilized to determine the heterogeneity 
among the included studies. P value <0.05 in combination 
with I2 value >50 % was considered significant heteroge-
neity. Random-effects models were applied in cases with 
significant heterogeneity. Subgroup analysis and sensitiv-
ity analysis were performed to dissect the heterogeneity. 
In addition, publication bias was determined using Egg-
er’s linear regression test and Begg’s funnel plots analysis. 
P-value <0.05 was considered statistically significant.
Results
Studies characteristics
A total of 255 relevant articles were identified based on 
electronic databases including PubMed, EMBASE, Web 
of Science, Ovid and Cochrane library. On the basis of 
the inclusion criteria, 17 eligible papers were enrolled 
in this meta-analysis (Fig.  1). The characteristics of the 
included studies are summarized in Table  1. A total of 
2094 patients from 17 studies between 2003 and 2016 
were included. The regions represented in the studies 
including Germany (n  =  2), Japan (n  =  2) and China 
(n =  13). Among these studies, the sample size ranged 
between 19 and 352, and 10 studies enrolled more 
than 100. Eleven types of human cancer were recorded 
including non-small cell lung cancer (NSCLC), hepato-
cellular carcinoma (HCC), gastric cancer (GC), pancre-
atic ductal adenocarcinoma (PDAC), colorectal cancer 
(CRC), clear cell renal cell carcinoma (ccRCC), esoph-
ageal squamous cell carcinoma (ESCC), esophageal 
cancer (EC), gallbladder cancer (GBC), bladder cancer, 
osteosarcoma and breast cancer. The levels of MALAT1 
expression were detected by reverse transcription quan-
titative polymerase chain reaction (qRT-PCR) or situ 
hybridization (ISH). The cut-off values in the included 
studies were inconsistent partly due to different detec-
tion methods. The clinical outcomes were also recoded 
including 12 studies for OS, 2 for DFS, 2 for PFS, 1 for 
DSS, and 12 for lymph node metastasis. HRs with the 
corresponding 95  % CIs were extracted from the origi-
nal data including 4 studies for OS, 3 for DFS, 1 for DFS, 
1 for RFS, and 1 for DFS, and calculated from Kaplan–
Meier Curves in 8 studies for OS, 1 for DFS and 1 for 
RFS.
Association between MALAT1 expression and survival 
in different types of cancers
A total of 12 studies including 1549 patients were 
recruited to assess the effect of MALAT1 overexpres-
sion on OS in different types of cancer. It was suggested 
that elevated MALAT1 expression predicted a poor out-
come for OS in 12 types of cancers (pooled HR = 1.91, 
95  % CI 1.49–2.34) with no heterogeneity (I2  =  0.0  %, 
P = 0.728) (Fig. 2). Furthermore, subgroup analysis was 
also conducted based on region of study, cancer type and 
sample size. Stratified analyses by region of study indi-
cated that the different effect of elevated MALAT1 on OS 
among different countries, including Germany (pooled 
HR = 1.72, 95 % CI 0.86–2.57), Japan (pooled HR = 1.55, 
95 % CI 0.72–2.38), and China (pooled HR = 2.22, 95 % 
CI 1.60–2.84) (Fig.  2a). A significant relationship was 
observed between MALAT1 overexpression and poor 
OS in the studies for digestive system cancers (pooled 
Fig. 1 The flow diagram of this meta-analysis
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HR =  1.77, 95  % CI 1.18–2.35), urinary system cancers 
(pooled HR = 2.95, 95 % CI 1.43–4.46), and respiratory 
system cancers (pooled HR =  1.72, 95  % CI 0.86–2.57) 
(Fig.  2b). In addition, the negative effect of MALAT1 
overexpression on predicting poor OS was shown in 
studies including <100 patients (pooled HR = 2.89, 95 % 
CI 1.05–4.73) as well as those with >100 patients (pooled 
HR = 1.86, 95 % CI 1.42–2.30) (Fig. 2c).
In addition, two studies including 224 patients 
reported HRs for DFS (Fig. 3b). High level of MALAT1 
expression was observed to be a negative factor for DFS 
(pooled HR  =  2.29, 95  % CI 1.24–3.35) with no het-
erogeneity (I2 =  0.0  %, P =  0.375). Two studies includ-
ing 368 patients reported HRs for RFS. Upregulation 
of MALAT1 expression was associated with poor RFS 
(pooled HR = 2.09, 95 % CI 0.81–3.37) with no heteroge-
neity (I2 = 0.0 %, P = 0.346).
Association between MALAT1 expression and lymph node 
metastasis
Twelve studies comprising 798 patients were pooled 
for the meta-analysis of lymph node metastasis. In 
high MALAT1 expression group, 393 patients (49.2  %) 
with cancer had lymph node metastasis, while only 405 
patients (50.8 %) in low MALAT1 expression group. Due 
to the presence of heterogeneity (I2 = 73.1 %, P < 0.001), 
we compared the incidence of lymph node metasta-
sis between these two groups with the random-effects 
model. The results found that the incidence of lymph 
node metastasis was higher in high MALAT1 expres-
sion group than that in low MALAT1 expression group 
(pooled OR  =  1.67, 95  % CI 1.30–2.15) (Fig.  3a). This 
result demonstrated that the patients with high levels 
of MALAT1 expression are more prone to lymph node 
metastasis in different systemic cancers.
Fig. 2 Forest plots of the included studies evaluating the hazard ratios (HRs) for MALAT1 for overall survival (OS). a Subgroup analysis of HRs of OS 
by factor of region; b subgroup analysis of HRs of OS by factor of cancer types; c subgroup analysis of HRs of OS by factor of sample size
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Publication bias and sensitivity analysis
To evaluate publication bias in this meta-analysis, the 
included studies were conducted using Egger’s linear 
regression test and Begg’s funnel plots analysis. The 
results of Egger’s linear regression test revealed no pub-
lication bias for the analysis of OS (t = 2.10, P = 0.062). 
The plots were also asymmetrically inverted funnels 
(Fig.  4). Due to the small number of studies, publica-
tion bias was not analyzed in the DFS and RFS groups. 
In addition, sensitivity analysis indicated that the pooled 
HR for deregulated MALAT1 associated with OS was not 
significantly affected by the exclusion of any of the stud-
ies (data not shown).
Discussion
Although these long noncoding transcripts were once 
considered to be simply transcriptional noise or cloning 
artifacts, numerous studies have suggested that lncRNAs 
are emerging as new players in diverse human diseases, 
especially cancers (Young and Ponting 2013; Qi and Du 
2013). Many studies have demonstrated that lncRNAs are 
involved in various biological processes, including modu-
lation of apoptosis and proliferation, drug resistance, the 
process of EMT, cancer progression and metastasis (Haj-
jari et al. 2014; Yang et al. 2014). An increasing number of 
studies have focused on the involvement of lncRNAs in 
cancer development and progression, and proposed them 
as potential biomarkers for cancer diagnosis or poten-
tial targets for cancer therapy (Cui et al. 2016; Yuan et al. 
2016; Xie et al. 2016; Liz and Esteller 2016).
MALAT1, regarded as one of the most familiar onco-
genic lncRNAs, was overexpressed in various cancers 
(Yoshimoto et al. 2016). MALAT1 could promote tumor 
progression through multiple mechanisms in various 
types of cancer. Increasing reports have demonstrated 
that MALAT1 could function as a promoter of cell 
Fig. 3 Forest plots of the included studies evaluating (a) the odds ratios (ORs) of MALAT1 for lymph node metastasis and (b) HRs for MALAT1 
expression for DFS, RFS and DSS
Fig. 4 Egger’s linear regression test (a) and Begg’s funnel plots analysis (b) were performed to evaluate publication bias
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proliferation and metastasis (Thum and Fiedler 2014). 
Jiao et al. reported that MALAT1 could possibly inhibit 
G2/M cell cycle arrest, thus promoting EMT in pancre-
atic cancer (Jiao et al. 2014). Then, Yao et al. found that 
MALAT1 knockdown induced a decrease in prolifera-
tion-enhanced apoptosis, inhibited invasion, and reduced 
colony formation and led to cell cycle arrest at the G2/M 
phase in esophageal squamous cell carcinoma (Yao et al. 
2016). Xu et al. (2016) revealed that MALAT1 promotes 
the proliferation of chondrosarcoma cell by activating 
Notch-1 pathway. Besides, Ji et  al. 2013 demonstrated 
that resveratrol could inhibit invasion and metastasis of 
colorectal cancer cells though MALAT1 mediated Wnt/
beta-catenin pathway . However, the mechanisms under-
lying aberrant expression of MALAT1 in cancers remain 
elusive. Some researcher discovered that upregulation of 
MALAT1 was mediated by the transcription factor Sp1 
in A549 lung cancer cells (Li et  al. 2015). Additionally, 
Wang et al. found that silencing of MALAT1 by miR-101 
and miR-217 inhibited proliferation, migration, and inva-
sion of esophageal cacner cells (Wang et al. 2015).
Recent studies found that overexpression of MALAT1 
correlated with poor prognosis of patients with nearly 
all types of cancer (Zheng et al. 2014; Zhang et al. 2015; 
Wang et al. 2016). However, the perplexity and inconsist-
ence arise from a wide range of studies due to heteroge-
neity. Therefore, a meta-analysis of 2094 cancer patients 
from 17 studies was undertaken to assess the prognostic 
value of MALAT1 expression in this study. The pooled 
data revealed that increased MALAT1 expression was 
significantly associated with poor OS, DFS and RFS, indi-
cating that MALAT1 has been shown to contribute to 
cancer progression and considered as a promising prog-
nostic biomarker for cancer patients. Furthermore, sub-
group analysis indicated that region of study (Germany, 
Japan or China), cancer type (digestive system cancers, 
urinary system cancers or respiratory system cancers) 
and sample size (more or less than 100) did not alter the 
significant predictive value of MALAT1 in OS from vari-
ous types of cancer. In addition, MALAT1 was originally 
discovered to be a marker for metastasis development 
in early stage lung adenocarcinoma (Ji et  al. 2003), and 
more recently it was shown to be a metastasis-related 
marker both in squamous cell carcinoma of the lung and 
hepatocellular carcinoma (Schmidt et al. 2011; Lai et al. 
2012). In this present study, we further verified that over-
expression of MALAT1 is associated with the incidence 
of lymph node metastasis in many types of cancer.
Some limitations of this meta-analysis should be 
acknowledged due to the discrete data across these clini-
cal studies. The major limitation of this meta-analysis was 
that we only included studies reporting HR or survival 
curves (except the data that cannot be calculated), and 
consequently some publications reporting on the prognos-
tic value of MALAT1 were excluded, thus the selection bias 
might be appeared. Secondly, a part of studies, especially in 
subgroups analyses, was lightly relative. Thirdly, only sum-
marized data rather than individual patient data were used. 
Fourthly, some of the HRs could not be directly obtained 
from the primary studies, we reconstruct the survival 
curves to extract the HR estimates or calculate them using 
the reported data. Finally, the cut-off value of high and low 
MALAT1 expression varied in different studies. Therefore, 
it is possible that our results might overestimate the prog-
nostic effects of abnormal MALAT1 expression on survival 
and lymph node metastasis in different types of cancer. We 
believed that more clinical studies should be conducted 
to evaluate potential prognostic role of MALAT1 in other 
types of cancer that have not been included.
Conclusion
This meta-analysis explored that elevated MALAT1 
expression is common to various types of cancer and 
might act as a novel predictive factor of poor prognosis 
and lymph node metastasis in different type of cancer. Fur-
thermore, the functional role of MALAT1 in the regulation 
of cell proliferation, apoptosis and metastasis suggested 
that MALAT1 may play a key role in tumor progression. 
Nevertheless, it is still necessary to conduct larger-size and 
better design studies to confirm our results.
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